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Abstract
Unlike other essential organs, the heart does not undergo tissue repair following injury. Human embryonic stem cells
(hESCs) grow indefinitely in culture while maintaining the ability to differentiate into many tissues of the body. As such, they
provide a unique opportunity to explore the mechanisms that control human tissue development, as well as treat diseases
characterized by tissue loss, including heart failure. MicroRNAs are small, non-coding RNAs that are known to play critical
roles in the regulation of gene expression. We profiled the expression of microRNAs during hESC differentiation into
myocardial precursors and cardiomyocytes (CMs), and determined clusters of human microRNAs that are specifically
regulated during this process. We determined that miR-125b overexpression results in upregulation of the early cardiac
transcription factors, GATA4 and Nkx2-5, and accelerated progression of hESC-derived myocardial precursors to an
embryonic CM phenotype. We used an in silico approach to identify Lin28 as a target of miR-125b, and validated this
interaction using miR-125b knockdown. Anti-miR-125b inhibitor experiments also showed that miR-125b controls the
expression of miRNA let-7d, likely through the negative regulatory effects of Lin28 on let-7. We then determined that miR-
125b overexpression inhibits the expression of Nanog and Oct4 and promotes the onset of Brachyury expression,
suggesting that miR-125b controls the early events of human CM differentiation by inhibiting hESC pluripotency and
promoting mesodermal differentiation. These studies identified miR-125b as an important regulator of hESC differentiation
in general, and the development of hESC-derived mesoderm and cardiac muscle in particular. Manipulation of miR-125b-
mediated pathways may provide a novel approach to directing the differentiation of hESC-derived CMs for cell therapy
applications.
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Introduction
Over five million people in the United States suffer with heart
failure [1] because unlike other essential organs, the heart does not
undergo tissue repair following injury [2]. Human embryonic stem
cells (hESCs) grow indefinitely in culture while maintaining the
ability to differentiate into many tissues of the body. As such, they
provide a unique opportunity to elucidate the mechanisms that
control human tissue development, as well as treat diseases
characterized by tissue loss, including heart failure. We previously
reported the identification of a human myocardial precursor
derived from hESCs that gives rise to atrial, ventricular, and
specialized conduction cardiomyocytes (CMs) [3]. The identifica-
tion and isolation of this precursor now allows us to investigate
further the regulatory events associated with early CM specifica-
tion from hESCs.
MicroRNAs (miRNAs/miRs) are small, non-coding RNAs that
were first identified as developmental mediators in C. elegans [4,5],
leading to the recognition that miRNAs play critical roles in the
regulation of gene expression. miRNAs primarily support post-
transcriptional gene silencing by targeting specific mRNA tran-
scripts for degradation or by inhibiting their translation [6].
miRNAs are thought to control the expression/translation of
.30% of all coding genes, and influence numerous biological
processes, including stem cell pluripotency [6], lineage specification
[7], tissue differentiation [8] and disease [9]. miRNAs are known to
regulate genes and pathways important in normal development,
and have been shown to promote tissue differentiation [6,8].
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e36121Studies of Dicer mutants in zebrafish and mice have specifically
implicated miRNA activity in early cardiac development. Zebra-
fish lacking Dicer show edematous cardiac tubes [10] suggesting
poor function, and cardiac-specific deletion of Dicer in mice
causes embryonic lethality at E12.5 with evidence of low-output
heart failure [11]. In collaboration with colleagues, we have shown
that miR-1 and -133 direct mesoderm formation, and that miR-1
directs subsequent cardiac differentiation, in hESCs by targeting
the Notch ligand Delta-like-1 [7].
To identify miRNAs that support CM differentiation from
hESCs, we profiled the expression of miRNAs during hESC
differentiation into myocardial precursors and CMs in culture, and
determined clusters of human miRNAs that appear to be
specifically regulated during this process. We investigated further
the role of miR-125b, and identified the Lin28/let-7 axis as the
target pathway through which it functions during mesoderm and
CM specification.
Results
miRNA expression is regulated during human CM
differentiation
To investigate the role of miRNAs in human CM differentia-
tion, we performed expression profiling of miRNAs expressed by
differentiating, a-myosin heavy chain (aMHC)-enhanced green
fluorescent protein (GFP)
+ myocardial precursors isolated from a
previously decribed myocardial reporter hESC line [3]. We
compared expression profiles of undifferentiated hESCs to
aMHC-GFP
+ cells sorted at days 8 and 14 of differentiation.
These time points coincide with induction of the early cardiac
transcription factor, Nkx2-5, and the definitive CM structural
protein, cardiac troponin I (cTnI), respectively [3]. To validate the
analysis, we evaluated expression of genes specifically involved in
cardiac myogenesis, CM differentiation, and cell cycle withdrawal
(Figure 1A–F). We observed upregulation of mRNAs involved in
cardiac myogenesis (Mef2C, HAND1, HAND2, TBX2, TBX5,
MLC2a, MLC2v, cTnI; Figure 1A,B), signaling pathways that
effect ventricular trabeculation and atrioventricular cushion
formation (BMP5/7/10 and BMP2/4, Nkx2-5, GATA4, Mef2C,
bMHC; Figure 1C,D), and cell cycle withdrawal coincident with
differentiation (p16
INK4, p15
INK4B, p21
CIP1, p27
KIP1, SCF;
Figure 1E,F) over the 14 day course of differentiation. We
confirmed the regulated expression of a subset of these genes by
quantitative real-time PCR (qPCR; Figure S1).
We then examined the expression patterns of .14,500 unique
miRNA sequences representing .900 human miRNAs from
sorted aMHC-GFP
+ cells at days 8 and 14 of differentiation
compared to undifferentiated hESCs. This identified 95 miRNAs
exhibiting $2-fold change in expression (False Discovery Rate
(FDR),0.05) at day 8 and 67 miRNAs exhibiting $2-fold change
in expression (FDR,0.05) at day 14. In addition, a heat map of
log2-fold change of all arrays relative to the average of the
undifferentiated hESC group for genes that were differentially
expressed in any of the comparisons, clustered using Euclidean
distance with average linkage, showed appropriate clustering
according to time point groups (Figure 1G). This confirmed that
the arrays were able to detect miRNA expression differences due
to biological differences between the time points examined.
Among those miRNAs demonstrating the most significant changes
in expression over the course of CM differentiation (Table 1),
several have previously been shown to play a role in early cardiac
specification, including miR-1 and miR-133 [7]. Others, such as
let-7, have been implicated more generally in the promotion of
terminal differentiation in vertebrates [12]. Of particular interest,
miR-125b previously has been observed as an important effector
of mesenchymal differentiation, including skeletal muscle and
bone [13,14]. In addition, it has been implicated in the
suppression of cellular proliferation in various cancers [15–17].
miR-125b expression is developmentally regulated
during human CM differentiation
To validate the expression of miR-125b over the course of
hESC differentiation, we analyzed the expression of miR-125b by
qPCR in undifferentiated H9 hESCs compared to H9 hESCs
cultured under differentiation conditions for 2, 3, and 4 days, and
H9-derived aMHC-GFP
+ hESCs at 8 and 14 days (Figure 2A).
This demonstrated that miR-125b expression increased .10-fold
by day 8 of hESC differentiation into CM precursors compared to
undifferentiated hESCs (p,0.001), consistent with expression
profiling analysis (Table 1). To confirm that miR-125b expression
was consistent across hESC lines, we analyzed its expression in the
unrelated H7 hESC line (Figure S2). The expression of miR-
125b was similar between differentiating H7 and H9 hESCs.
miR-125b promotes CM differentiation from hESCs
To determine the effects of miR-125b on CM differentiation
specifically, we transfected proliferating hESCs with pre-miR-125b
and anti-miR-125b inhibitor to achieve overexpression and
knockdown of miR-125b, respectively (Figure 2B, C). Expression
analysis of miR-125b by qPCR demonstrated a 4.3-fold decrease
in miR-125b expression with anti-miR compared to control
(0.2360.03 vs. 1.0060.09; p,0.01), and a .500-fold increase in
miR-125b expression with pre-miR compared to control
(541.44619.29 vs. 1.0060.09; p,0.001) (Figure 2B). To
evaluate miR-125b binding and activity with anti- and pre-miR
transfection, we co-transfected hESCs with a luciferase reporter
containing the predicted miR-125b binding site (Figure 2C). This
demonstrated a dose-dependent decrease in luciferase activity with
expression of pre-miR-125b compared to control cells (minimum
relative light units (RLU) 52.7869.63 vs. 155.50612.00; p,0.01),
and a dose-responsive increase in luciferase activity with
expression of anti-miR-125b (maximum RLU 373.12623.55 vs.
155.50612.00; p,0.01) (Figure 2C). This analysis confirmed
appropriate manipulation of miR-125b expression, binding, and
activity in culture with pre- and anti-miR-125b constructs.
We then examined the effects of miR-125b overexpression and
knockdown on the expression of CM-specific genes over the course
of hESC differentiation (Figure 3). Expression analysis of the
early cardiac transcription factor, GATA4, with miR-125b
overexpression showed premature upregulation of GATA4
expression in undifferentiated hESCs (1.6760.03 vs. 1.0060.03;
p,0.05) as well as hESCs grown in differentiation medium for 2
days (2.2460.08 vs. 1.2060.05; p,0.01) before GATA4 expres-
sion is normally observed [3] (Figure 3A). Appropriate expression
of GATA4 in hESCs differentiated for 8 days was unaffected by
overexpression of miR-125b (1.9160.19 vs. 2.1360.04; p.0.05).
Interestingly, overexpression of miR-125b in undifferentiated
hESCs did not effect Nkx2-5 expression (1.1160.03 vs.
1.0060.04; p.0.05); however, it did result in premature
upregulation of Nkx2-5 expression in hESCs cultured in
differentiation media for 2 days (2.4060.05 vs. 1.0160.02;
p,0.01), before Nkx2-5 expression is normally seen [3]
(Figure 3A). Knockdown of miR-125b had the opposite effects
on GATA4 and Nkx2-5 expression over the course of hESC
differentiation. These data suggested that miR-125b promotes the
onset of CM differentiation from hESCs.
Expression of genes that are active later during CM differen-
tiation was similarly affected by miR-125b overexpression and
miR-125b and Mesoderm Fate Determination
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e36121knockdown (Figure 3B). Normally, expression of genes associated
with embryonic ventricle (aMHC, cardiac troponin T (cTnT),
ventricular myosin light chain-2), atrium (aMHC, cTnT, sarco-
lipin), and conduction tissue (connexin 43) is not observed in
hESC-derived CMs until day 8 of differentiation [3]. However,
premature expression of all of these genes was observed in hESCs
Figure 1. Differentiation of an aMHC-GFP reporter hESC line recapitulates cardiac myogenesis and identifies developmentally
regulated miRNAs. mRNA expression profiles of hESC-derived, aMHC-GFP
+ myocardial precursors sorted at days 8 (A, C, E) and 14 (B, D, F)o f
differentiation demonstrated upregulated expression (red) of genes involved in cardiac myogenesis (A, B), cellular differentiation into CMs (C, D),
and withdrawal from the cell cycle (E, F). Abl1, c-abl non-receptor tyrosine kinase; ALK, BMP receptor; ATF2, activating transcription factor 2; ATM/
ATR, ; ATP2A2, cardiac calcium transporting ATPase; BMP, bone morphogenic protein; BMPR, BMP receptor; CDK, cyclin-dependent kinase; DP-1,
transcription factor Dp-1; E2F, E2F transcription factor; EBP1, ErbB3 binding protein; GATA, GATA binding protein; HAND, heart and neural crest
derivatives expressed factor; HDAC, histone deacetyltransferase; ISL1, islet-1; MEF2C, myocyte enhancer factor 2C; MLC2v, ventricular myosin light
chain 2; MYH6, a-myosin heavy chain; MYL3, ventricular myosin light chain 3; MYL4, atrial myosin light chain 4; MYLPF, fast skeletal myosin light chain;
MYOCD, myocardin; MYOM1, myomesin 1; NKX2.5, NK2 transcription factor related locus 5; NPPA, natriuretic peptide A; NPPB, natriuretic peptide B;
NR2F, nuclear receptor subfamily 2, group F; p15INK4, cyclin-dependent kinase inhibitor 2B; p16INK4, cyclin-dependent kinase inhibitor 2A; p21Cip1,
cyclin-dependent kinase inhibitor 1A; p27Kip1, cyclin-dependent kinase inhibitor 1B; p53, 53 kD tumor protein ; Rb, retinoblastoma protein; SCF, Skp-
Cullin-F-box containing E3 ubiquitin ligase complex; SIN3A, SIN3 transcription factor homolog A; SMAD, SMA/mothers against decapentaplegic;
SMYD1, SET and MYND domain containing protein; Suv39H1, suppressor of variegation 3–9 homolog 1; TAK1, mitogen-activated protein kinase
kinase kinase 7; TBX, T-box transcription factor; TGF-b, transforming growth factor-b; TnI, cardiac troponin I; TNNC1, troponin C type 1; TNNI1,
troponin I type 1; TNNT2, cardiac troponin T ; TTN, titin; WNT11, wingless-type MMTV integration site family member 11; ZFPM2, zing finger protein
multitype 2; b-MHC, b-myosin heavy chain. G) Relative miRNA expression in aMHC-GFP
+ hESCs sorted at days 8 and 14 of differentiation (two samples
each), compared to undifferentiated aMHC-GFP reporter hESCs. Heat map shows log2-fold change (sample intensity/mean intensity for
undifferentiated group) for the 156 miRNAs that had statistically significant differences (false discovery rate (FDR),0.05) of at least 2-fold in any
pairwise comparison between the three groups.
doi:10.1371/journal.pone.0036121.g001
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medium for only 2 days (Figure 3B). Similarly, inhibition of these
genes was seen in anti-miR-125b-transfected hESCs cultured in
differentiation medium for 8 days (Figure 3B). Of note, the
expression of connexins 40 and 45, which are expressed later
during development of the conduction system, were not affected
by miR-125b overexpression until day 8, after the onset of Cx43
expression (Figure 3B). These data support a persistent role for
miR-125b that extends into the later stages of CM development
during hESC differentiation.
In silico prediction of miR-125b targets
We used Target Scan Human (Release 5.2; MIT) to predict
potential targets of miR-125b. Lin28 was among those targets
identified with the highest probabilities of conserved targeting
(PCT; [18]), based on seed match [19], site-type contribution [20],
39 pairing contribution outside the seed region [20], overall
context score [20], and conserved branch length score [18]
(Figure 4A). These criteria compared favorably with those for the
previously validated interaction between let-7a and Lin28 [21]
(Figure 4A). The putative miR-125b binding site in the Lin28 39
untranslated sequence was also highly conserved among mammals
(Figure 4B). In addition, Lin28 has been identified as a target of
miR-125b during neuronal differentiation of mouse P19 embry-
onal carcinoma cells [22], and more recently, miR-125b has been
shown to target Lin28 during mouse embryoid body formation
[23]. Taken together, this analysis strongly supported the
identification of Lin28, recognized for its role in the maintenance
of stem cell pluripotency [24], as a potential target for human
miR-125b.
Table 1. miRNAs exhibiting significant change in expression during CM differentiation.
miRNAs with fold change .2 (FDR,0.05)
Day 8 vs. Undifferentiated Day 14 vs. Undifferentiated
Fold Change FDR AdjP Fold Change FDR AdjP
let-7d* 2.5 0.002 0.050 0.4 0.015 0.706
miR-1 11.1 0.002 0.084 16.9 ,0.001 0.020
miR-23b 2.2 0.008 0.417 3.0 0.002 0.044
miR-30d 2.7 0.002 0.074 5.4 ,0.001 0.002
miR-125a-5p 2.2 0.004 0.180 4.2 ,0.001 0.003
miR-125b 7.8 0.001 0.032 4.2 ,0.001 0.003
miR-129-3p 3.7 ,0.001 0.009 4.4 ,0.001 0.002
miR-133a 75.4 ,0.001 ,0.001 72.5 0.000 ,0.001
miR-133b 48.8 ,0.001 ,0.001 56.2 ,0.001 ,0.001
miR-143 20.5 0.002 0.063 43.8 ,0.001 0.010
miR-145 43.1 ,0.001 ,0.001 59.7 0.000 ,0.001
miR-197 8.3 ,0.001 0.003 2.3 0.010 0.438
miR-210 3.3 0.003 0.148 8.6 ,0.001 0.003
miR-328 6.5 ,0.001 0.024 2.4 0.019 0.908
miR-490-3p 3.6 ,0.001 0.024 7.7 ,0.001 0.001
miR-532-3p 2.5 0.002 0.071 2.6 0.002 0.041
miR-574-3p 17.6 ,0.001 0.001 3.4 0.004 0.142
miRNAs with fold change ,0.5 (FDR,0.05)
Day 8 vs. Undifferentiated Day 14 vs. Undifferentiated
Fold Change FDR AdjP Fold Change FDR AdjP
miR-7 0.30 ,0.001 0.016 0.31 ,0.001 0.011
miR-124 0.13 ,0.001 ,0.001 0.36 0.001 0.039
miR-183 0.24 0.001 0.031 0.46 0.011 0.525
miR-187 0.16 ,0.001 0.002 0.15 ,0.001 0.001
miR-221 0.08 ,0.001 0.004 0.16 0.001 0.013
miR-222 0.09 ,0.001 ,0.001 0.15 ,0.001 0.003
miR-302a 0.02 ,0.001 0.006 0.01 ,0.001 ,0.001
miR-302b 0.02 ,0.001 ,0.001 0.01 ,0.001 ,0.001
miR-302d 0.03 ,0.001 0.012 0.01 ,0.001 0.002
miR-367 0.05 0.002 0.084 0.01 ,0.001 0.003
miR-378 0.27 0.001 0.028 0.45 0.008 0.299
miR-494 0.16 0.001 0.039 0.25 0.004 0.129
doi:10.1371/journal.pone.0036121.t001
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differentiation
To determine whether Lin28 expression inversely parallels miR-
125b expression during CM differentiation, we analyzed Lin28
transcription by qPCR in undifferentiated hESCs compared to
aMHC-GFP
+ myocardial precursors and CMs sorted from
cultures grown in differentiation medium for 8 and 14 days,
respectively (Figure 4C). We observed a significant decrease in
Lin28 mRNA over time (Day 8: 0.2760.02 vs. 1.0060.1,
p,0.001; Day 14: 0.1360.06 vs. 1.0060.1, p,0.001), as would
be predicted by negative post-transcriptional regulation of Lin28
by miR-125b. To determine whether the change in Lin28
expression with differentiation was mediated by miR-125b, we
knocked down miR-125b in differentiating hESCs (Figure 5A),
and assayed Lin28 protein expression (Figure 5B). In undiffer-
entiated cells, expression of anti-miR-125b lead to an increase in
Lin28 expression. As Lin28 expression decreased with hESC
differentiation, transfection with anti-miR-125b had a similar
effect compared to untransfected cells, although to a lesser extent.
This demonstrated that the effects of miR-125b on early hESC
differentiation likely occur through inhibition of Lin28.
Since Lin28 has been shown to exert its effects on pluripotency
through binding to and inactivation of let-7, we examined the
effect of miR-125b knockdown on let-7d and let-7d* expression in
differentiating hESCs. We focused on let-7d and let-7d* because
let-7d* demonstrated regulated expression during our initial
expression profiling screen (Table 1). MiR-125b knockdown
resulted in parallel downregulation of let-7d expression
(Figure 6A). Interestingly, a similar effect on let-7d* was not
observed (data not shown), suggesting that its expression during
hESC differentiation is regulated independent of miR-125b. Since
Figure 2. miR-125b expression increases with differentiation in hESCs. A) Relative expression of endogenous miR-125b in undifferentiated
hESCs (Undiff) and hESCs grown in differentiation medium for 2, 3, and 4 days, or sorted aMHC-GFP
+ hESCs differentiated for 8 and 14 days (as for
Figure 1) was assessed by qPCR. A significant increase in miR-125b expression was observed in sorted aMHC-GFP
+ hESCs at day 8 and sustained
through day 14 of differentiation. Data shown are mean6s.e.m. (N=3). ***, p,0.001. B) Relative expression of miR-125b in undifferentiated hESC
cultures transfected with 30 nM anti-miR-125b inhibitor (anti-125b) or pre-miR-125b (pre-125b), as analyzed by qPCR, showed appropriate down- or
up-regulation of miR-125b expression, respectively, compared to untransfected control (Ctl) hESCs. C) Relative binding and activity of miR-125b in
undifferentiated hESC cultures transfected with anti-125b and pre-125b, as assessed by luciferase reporter activity, demonstrated appropriate up- and
down-regulation of luciferase activity in a dose-dependent manner, respectively, compared to hESCs transfected with luciferase reporter alone (Ctl).
Data shown are mean6s.e.m. (N=3). **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0036121.g002
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Lin28 [25], suggesting that let-7 might participate in negative
feedback to its negative regulator, we examined the effect of let-7d
knockdown on Lin28 expression (Fig. 6B). Surprisingly, expres-
sion of anti-let-7d in differentiating hESCs resulted in downreg-
ulation of Lin28, suggesting that let-7d may, in fact, positively
regulate its negative regulator, Lin28, during hESC differentiation.
miR-125b promotes early events of cardiac mesoderm
development by inhibiting embryonic stem cell
pluripotency and promoting mesodermal differentiation
Since Lin28 regulates pathways controlling pluripotency and
differentiation [24], we examined whether manipulation of miR-
125b expression in undifferentiated and differentiating hESCs
affected the expression of other pluripotency genes, i.e., Nanog
and Oct4, as well as genes expressed early during development of
mesoderm, ectoderm, and endoderm (i.e., Brachyury, Nestin, and
a-fetoprotein, respectively) (Figure 7). In undifferentiated hESCs,
overexpression of pre-miR-125b suppressed Nanog and Oct4
expression (Nanog: 0.4760.04 vs. 1.0060.03, p,0.05; Oct4:
0.7460.04 vs. 1.0060.04, p,0.05), and promoted the premature
expression of Brachyury (1.9360.08 vs. 1.0060.03, p,0.01),
compared to control cells. Conversely, expression of anti-miR-
125b in hESCs grown in differentiation medium for 2 days (early
differentiation) resulted in higher levels of Nanog and Oct4
expression (Nanog: 1.7460.06 vs. 0.8760.01, p,0.05; Oct4:
1.6560.04 vs. 0.8460.01, p,0.05), and suppression of Brachyury
(1.8660.01 vs. 2.6860.01, p,0.05). Interestingly, Nestin, a
marker of primitive ectoderm, did not appear to be affected by
miR-125b expression, and the primitive endodermal marker, a-
fetoprotein, showed expression patterns opposite of those for
Brachyury with overexpression of pre-miR-125b (undifferentiat-
ed/pre-miR-125b: 0.4360.03 vs. 1.0060.09, p,0.05; differenti-
ated/anti-miR-125b: 3.1860.25 vs. 2.2360.21, p,0.05). These
data suggest that miR-125b promotes withdrawal from the
pluripotency state, likely through its effects on Lin28, and that it
also preferentially favors the development of mesoderm, including
cardiac muscle, over endoderm.
Discussion
The small regulatory RNA, miR-125b, has previously been
shown to function during the differentiation of tissues from
mesodermal precursors, including osteoblasts from mesenchymal
stem cells [14] and skeletal muscle from C2C12 myoblasts [13]. In
addition, recent studies have implicated miR-125b in the early
commitment of stem cells to skin elements [26]. However, the
specific targets through which miR-125b mediates these effects are
not completely known. We now demonstrate a role for miR-125b
Figure 3. miR-125b promotes the expression of cardiac-specific genes during hESC differentiation. hESCs were transfected with pre-
miR-125b (pre-125b) or anti-miR-125b inhibitor (anti-125b), cultured in differentiation medium for 2 or 8 days, and analyzed for expression of cardiac-
specific mRNAs by qPCR. A) Overexpression of pre-125b induced premature expression of the early cardiac transcription factor, GATA4, in
undifferentiated hESCs (Undiff), and promoted the early expression of both GATA4 and Nkx2-5 in hESCs cultured in differentiation medium for only 2
days, before the usually observed expression of these transcription factors during CM differentiation. Anti-125b suppressed the expression of Nkx2-5
at day 8 of differentiation, but had little effect on GATA4 at this time point. Data shown are mean6s.e.m. (N=3). *, p,0.05; **, p,0.01. B)
Overexpression of pre-125b resulted in the early expression of CM structural genes at day 2, before they are usually observed, while expression of
anti-125b inhibited the expression of these genes at day 8, when they begin to be expressed in differentiating hESCs. aMHC, a-myosin heavy chain;
cTnT, cardiac troponin T; SLN, sarcolipin; MLC2v, ventricular myosin light chain 2; Cx, connexin. Data shown are mean6s.e.m. (N=3). *, p,0.05; **,
p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0036121.g003
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hESCs, and that this likely occurs in part through miR-125b
targeting of the pluripotency factor, Lin28.
Lin28 has been identified as a marker of undifferentiated
embryonic stem cells [27], and has been used to enhance the
efficiency of the formation of induced pluripotent stem cells from
Figure 4. Lin28 is a predicted target of miR-125b in differentiating hESCs. A) In silico analysis of potential miR-125b targets using Target
Scan Human identified Lin28 as a potential target. Seed match refers to the match between a sequence in the 39 untranslated region (UTR) of the
putative target gene and positions 2–8 of the mature miRNA; site-type contribution reflects the average contribution of each site identified; 39 pairing
contribution describes the impact of miRNA-target complementarity outside the seed region; local AU contribution is a measure of the target
transcript AU content 30 nucleotides upstream and downstream of the predicted site; position contribution reflects the distance to the nearest end
of the target’s UTR. For each of these criteria, a more negative score indicates a more favorable site. The context score is the sum of the contributions
of site-type, 39 pairing, local AU, and position criteria. Conserved branch length is the sum of phylogenetic branch lengths between species that
contain the site. The probability of conserved targeting (PCT) reflects the Bayesian estimate of the probability that a site is evolutionarily conserved
through selective advantage, rather than by chance. These criteria applied to miR-125b/Lin28 were similar to those for the established let-7a/Lin28
interaction. B) Conservation among mammals of the miR-125b binding site in the 39 UTR of Lin28. Bta, cow; Cfa, dog; Cpo, guinea pig; Dno, armadillo;
Eca, horse; Eeu, hedgehog; Gga, chicken; Hsa, human; Laf, elephant; Mdo, opossum; Mml, rhesus; Mmu, mouse; Ocu, rabbit; Ptr, chimpanzee; Rno, rat;
Sar, shrew. C) Undifferentiated aMHC-GFP reporter hESCs (Undiff) and aMHC-GFP
+ CMs sorted from reporter hESCs grown in differentiation medium
for 8 or 14 days were evaluated for Lin28 expression by qPCR. Endogenous expression of Lin28 mRNA declined with CM differentiation. Data shown
are mean6s.e.m. (N=3). ***, p,0.001.
doi:10.1371/journal.pone.0036121.g004
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in hESC fate determination, specifically the switch from self-
renewal to differentiation, and also implicated Lin28 in promoting
the formation of specific tissues [29]. Our experiments underscore
the role of Lin28 in early hESC differentiation, and trace its
regulation to miR-125b.
Figure 5. Lin28 expression is controlled by miR-125b in
differentiating hESCs. Untransfected hESCs (Cntl) or hESCs trans-
fected with anti-miR-125b inhibitor (anti-125b) were cultured in
differentiation medium for 2 or 8 days. A) Cells were analyzed for
expression of miR-125b by qPCR. Appropriate downregulation of
mature miR-125b was seen in both undifferentiated and differentiating
hESCs. Data shown are mean6s.e.m. (N=3). **, p,0.01; ***, p,0.001.
B) Cell lysates were assayed for Lin28 by immunoblot analysis
compared to undifferentiated cells (Undiff). Lin28 protein expression
was noticeably decreased in hESCs differentiated for 2 or 8 days
compared to undifferentiated cells, while transfection with anti-125b
induced Lin28 expression in undifferentiated as well as differentiating
cells (TOP). Actin was used as a loading control. Representative results
are shown. Quantitation of fluorescent signals is shown (BOTTOM). Data
shown are mean6s.e.m. (N=3). *, p,0.05; **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0036121.g005
Figure 6. Lin28-mediated let-7d expression is regulated by
miR-125b in differentiating hESCs. Untransfected hESCs (Cntl) or
hESCs transfected with anti-miR-125b (anti-125b) or anti-let-7d (anti-let-
7d) inhibitor were cultured in differentiation medium for 2 or 8 days. A)
Cells were analyzed for expression of let-7d by qPCR. Inhibition of miR-
125b downregulated expression of let-7d in both undifferentiated and
differentiating hESCs. Data shown are mean6s.e.m. (N=3). **, p,0.01;
***, p,0.001. B) Cell lysates were assayed for Lin28 by immunoblot
analysis compared to undifferentiated cells (Undiff). Lin28 protein
expression was noticeably decreased in undifferentiated hESCs
transfected with anti-let-7d compared to untransfected undifferentiated
cells. This effect was seen to a lesser extent in hESCs differentiated for 2
days. However, the effect of let-7d inhibition on Lin28 was lost by day 8
of differentiation (TOP). Actin was used as a loading control.
Representative results are shown. Quantitation of fluorescent signals
is shown (BOTTOM). Data shown are mean6s.e.m. (N=3). *, p,0.05; **,
p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0036121.g006
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to play a role in cell differentiation based on temporal expression
during development [30] and low levels of expression in
undifferentiated tumors [31]. Recent studies have elucidated the
mechanisms by which let-7 biogenesis and activity are inhibited by
Lin28 [32,33]. Since a let-7/Lin28 negative feedback loop has also
been shown in vertebrates [25], we were surprised to observe that
let-7d appears to positively regulate Lin28 expression. Although
further investigation of this observation is warranted, this positive
feedback loop may somehow titrate the tempo of differentiation
and withdrawal from the pluripotent state. The effect of let-7d on
Lin28 also may be one of several signals converging on the Lin28
axis, with the balance of these inputs determining hESC fate.
While our experiments indicate that miR-125b plays a
regulatory role in the early stages of hESC differentiation, likely
through targeting Lin28, it also appears to induce the formation of
mesoderm, and cardiac mesoderm in particular. This, however, is
not likely to involve Lin28, as Lin28 expression decreases
dramatically with hESC differentiation, suggesting that other
potential targets of miR-125b may be responsible. Target Scan
identified 604 conserved targets for miR-125b, with .50
demonstrating an aggregate PCT .0.95 (Table S1), and 49 with
a total context score #20.45 (Table S2). Some of these target
gene products may participate in pathways that promote
endoderm or ectoderm, or even non-cardiac mesoderm, and
miR-125b may mediate its developmental preferences by
negatively regulating these. Further investigation is warranted to
elucidate these mechanisms.
In summary, using an aMHC-GFP reporter hESC line, we
have identified miR-125b as an important regulator of hESC
differentiation in general, and the development of hESC-derived
mesoderm including cardiac muscle. Further investigation of miR-
125b-mediated pathways will provide important insight into the
regulation of human myocardial development, and provide a
novel approach to directing the differentiation of hESC-derived
CMs for cell therapy applications.
Materials and Methods
hESC culture and differentiation
All work with hESCs was done with the approval of the UCSF
Stem Cell Research Oversight Committee. The aMHC-GFP
myocardial reporter [3], H9 (WA09; WiCell) and H7 (WA07;
WiCell) hESC lines were maintained on irradiated mouse
embryonic fibroblast feeder cells [3] in a medium comprised of
Knockout DMEM (Invitrogen) supplemented with 20% Knockout
Serum Replacement (Invitrogen), 2 mM glutamine, 0.1 mM
nonessential amino acids, 0.1 mM b-mercaptoethanol and
15 ng/ml recombinant human FGF-basic (R&D Systems).
Differentiation was initiated by human embryoid body (hEB)
formation in suspension as previously described [3,34]. Briefly,
colonies of hESCs were dissociated into clusters by exposure to
Collagenase IV (Sigma-Aldrich), then allowed to differentiate in a
medium comprised of Knockout DMEM (Invitrogen) supplement-
ed with 20% Defined Fetal Bovine Serum (Hyclone), 2 mM
glutamine, 0.1 mM non-essential amino acids, and 0.1 mM b-
mercaptoethanol. After 4 days in suspension, hEBs were attached
to gelatin-coated 12-well culture plates and allowed to differentiate
for an additional 14 days. For expression profiling experiments,
hEBs were dissociated with TrypLE Express (Invitrogen) to
generate single cell suspensions, stained with propidium iodide
to distinguish between live and dead cells, and sorted on the basis
of GFP expression using a FACSAria (Becton Dickinson) with
standard filter sets using previously described methods [3].
mRNA expression profiling
Sample preparation, labeling, and array hybridizations were
performed as previously described [3], according to standard
protocols from the UCSF Shared Microarray Core Facilities and
Agilent Technologies (http://www.arrays.ucsf.edu and http://
www.agilent.com). Total RNA quality was assessed using a Pico
Chip on an Agilent 2100 Bioanalyzer (Agilent Technologies).
RNA was amplified using the Sigma whole transcriptome
amplification kit following the manufacturer’s protocol (Sigma-
Aldrich), and subsequent Cy3-CTP labeling was performed using
the NimbleGen one-color labeling kit (Roche-NimbleGen). The
size distribution and quantity of the amplified product was assessed
using an Agilent 2100 Bioanalyzer and a Nanodrop ND-8000
(Nanodrop Technologies); the labeled DNA was assessed using the
Nandrop 8000, and equal amounts of Cy3 labeled target were
hybridized to Agilent human whole genome 4x44K Ink-jet arrays.
Hybridizations were performed for 14 hrs, according to the
manufacturers protocol. Arrays were scanned using an Agilent
microarray scanner and raw signal intensities were extracted with
Figure 7. miR-125b inhibits the expression of pluripotency genes and promotes mesodermal development during hESC
differentiation. hESCs were transfected with pre-miR-125b (pre-125b) or anti-miR-125b inhibitor (anti-125b), cultured in differentiation medium for
2 days, and analyzed for expression of pluripotency or early germ layer mRNAs by qPCR. Overexpression of pre-125b suppressed the expression of
pluripotency markers, Nanog and Oct4, in undifferentiated hESCs and induced premature expression of the early mesodermal marker, Brachyury.
Anti-125b promoted the expression of Nanog and Oct4 at day 2 of differentiation, and conversely inhibited the normal expression of Brachury at this
time point. AFP, a-fetoprotein. Data shown are mean6s.e.m. (N=3). *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0036121.g007
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were further analyzed using Ingenuity Pathways Analysis (Inge-
nuity Systems) to identify biological pathways involved in CM
differentiation. The false discovery rate (FDR) from the data set
was used for canonical pathways analysis.
Data were normalized using the quantile normalization method
[35]. No background subtraction was performed, and the median
feature pixel intensity was used as the raw signal before
normalization. A one-way ANOVA linear model was fit to the
comparison to estimate the mean M values and calculated FDR
for each gene for the comparison of interest. All procedures were
carried out using functions in the R package limma in Bioconductor
[36,37]. All data comply with MIAME standards for microarray
experiments [38], and have been deposited in Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/; Accession Num-
ber GPL6480).
miRNA expression profiling
Sample preparation, labeling, and array hybridizations were
performed according to standard protocols from the UCSF Shared
Microarray Core Facilities and Agilent Technologies (http://
www.arrays.ucsf.edu and http://www.agilent.com). Total RNA
quality was assessed using a Pico Chip on an Agilent 2100
Bioanalyzer (Agilent Technologies). RNA was labeled with Cy3-
CTP using the miRCURY LNA microRNA power labeling kit
(Exiqon), according to manufacturers protocol. Labeled RNA was
hybridized to Agilent custom UCSF miRNA v3.4 multi-species
8x15K Ink-jet arrays (Agilent Technologies). Hybridizations were
performed for 16 hrs, according to the manufacturers protocol
(Agilent Technologies). Arrays were scanned using the Agilent
microarray scanner (Agilent Technologies) and raw signal
intensities were extracted with Feature Extraction v10.1 software
(Agilent Technologies).
The dataset was normalized using quantile normalization [35]
with a filter to remove all probes where the max log2 signal across
arrays was less than 5. No background subtraction was performed,
and the median feature pixel intensity was used as the raw signal
before normalization. The filter for low intensity probes was used
to prevent the prevalence of so many low-intensity probes (which
tend to have smaller variance) from underestimating global and
per-gene estimates of variance. A one-way ANOVA linear model
was fit to the comparison to estimate the mean M values and
calculated FDR and p-value for each miRNA for the comparison
of interest. Adjusted p-values were produced using standard
methods [39]. All procedures were carried out using functions in
the R package limma in Bioconductor [36,37]. All data comply
with MIAME standards for microarray experiments [38], and
have been deposited in Gene Expression Omnibus (http://www.
ncbi.nlm.nih.gov/geo/; Accession Number to be provided during
review).
Quantitative real-time PCR
For analysis of transcript expression, GFP
+ hESCs were sorted
by FACS at indicated time points. RNA was isolated and cDNA
synthesized from ,50,000 hEB-derived cells or undifferentiated
hESCs using the Taqman Gene Expression Cells-to-CT kit
(Ambion). cDNA was quantitated using a Nanodrop ND-1000
Spectrophotometer (Nanodrop Technologies, ND Software ver-
sion 3.3.0). Linear pre-amplification of target sequences was
accomplished using the Applied Biosystems PreAmp system.
Relative expression was determined using the TaqMan Assay
(Applied Biosystems) on an ABI 7300 Real-Time PCR system with
the following primer pairs (ABI): Lin28 (Hs00702802_s1), GATA4
(Hs00171403_m1), Nkx2-5 (Hs00231763_m1), sarcolipin (Hs00161903_
m1;Hs01888464_s1), MLC2v (Hs00166405_m1;Hs01125721_m1),
aMHC (Hs00411908_m1), cTnT (Hs00165960_m1), a-fetoprotein
(Hs00173490_m1), nestin (Hs00707120_s1), Cx43 (Hs00748445_s1),
Cx40 (Hs00979198_m1), Cx45 (Hs00271416_s1), and GAPDH
(4326317E). Cycle times to detection were normalized against a
reference gene, GAPDH, and relative changes were calculated using
ABI Version 1.4 Sequence Detection Software.
For analysis of miRNA expression, miRNAs were isolated from
hESCs or sorted cells using the mirVana miRNA Isolation kit
(Ambion), and cDNA was reverse transcribed using the TaqMan
MicroRNA RT kit (ABI). Following linear pre-amplification of
miRNA sequences using the Applied Biosystems PreAmp system,
relative expression was determined using singleplex TaqMan
Assays (Applied Biosystems) with primer sets for human miR-125b
(Applied Biosystems; 000449) and let-7d (Applied Biosystems;
4427975). Cycle times to detection were normalized against two
reference sequences, RNU44 (001094) and RNU48 (001006), and
relative changes were calculated as described.
Overexpression and knockdown of miR-125b and let-7d
Pre-miR-125b precursor (Invitrogen/Ambion; PM10148), anti-
miR-125b inhibitor (Invitrogen/Ambion; AM10148), and anti-let-
7d inhibitor (Invitrogen/Ambion; AM1178) were transfected into
undifferentiated hESCs using DharmaFECT Duo reagent (Dhar-
macon) according to the manufacturer’s instructions. Initial dose-
response experiments were performed with 15, 30, and 45 nM
pre- and anti-miR reagent, as shown in Figure 2C. Once the
optimum dose of 30 nM was established, all subsequent
experiments were performed with 30 nM pre- or anti-miR
reagent. For experiments with undifferentiated hESCs, cells were
allowed to recover for 2 days before analysis. For experiments with
differentiating hESCs, cells were re-transfected every 2 days until
analysis.
Luciferase reporter assay
Luciferase assays were performed in whole cell lysates using the
dual luciferase reporter assay system (Promega) as described
previously [40]. pRL-TK (Promega) encoding constitutively
expressed Renilla reniformis luciferase was included in each
transfection to normalize for transfection efficiency. At the time
of pre-miR-125b and anti-miR-125b transfection, hESCs were co-
transfected with 0.2 mg pMiR-125b-Luc reporter plasmid (Signo-
sis; LR-0020) together with 0.1 mg of pRL-TK. pMiR-125b-Luc
expresses Photinus pyralis luciferase under control of a CMV
promoter, regulated by the presence of a miR-125b binding site
within the 39 UTR of the luciferase coding sequence. After 48 hrs,
cell lysates were assayed for Photinus and Renilla luciferase activities.
Photinus luciferase activity was normalized against Renilla luciferase
activity and expressed as relative light units. Assays were
performed in triplicate and repeated at least three times.
Quantitative near-infrared fluorescence immunoblot
analyis
Protein expression was determined by near-infrared fluores-
cence immunoblot analysis using a LI-COR Odyssey CLx (LI-
COR Biosciences, Lincoln, NE) with a .4 log dynamic range.
Briefly, whole cell lysates were separated on sodium dodecyl sulfate
(SDS)–polyacrylamide gels (10%), then transferred in Tris-glycine,
20% methanol, 0.01% SDS onto PVDF membrane (Immobilon;
Millipore) as previously described [41]. Membranes were blocked
with phosphate-buffered saline-based Odyssey blocking buffer
(927-40100; LI-COR), incubated with primary antibody at 1:500
dilution in blocking buffer, then infrared dye-linked secondary
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antibodies included polyclonal rabbit anti-human Lin28 (H-44)
(sc-67266; Santa Cruz Biotechnology) and goat anti-human actin
(I-19) (sc-1616; Santa Cruz Biotechnology). Secondary antibody
consisted of IRDye 680LT-conjugated goat anti-rabbit IgG (H+L)
(827-11081; LI-COR). Bound antibodies were detected and
quantitated with Odyssey v 3.0 software (LI-COR Biosciences,
Lincoln, NE).
Statistical analysis
For comparison of quantitative real-time PCR and immunoblot
quantitation data, analysis of variance (ANOVA) with Fisher’s
post-hoc test was used. Where ANOVA indicated significant
differences among groups, multiple comparisons were made using
Student’s t- test with Bonferroni correction. A p-value less than
0.05 was considered significant.
Supporting Information
Figure S1 Validation of gene expression during cardio-
myocyte differentiation. qPCR analysis of sorted aMHC-
GFP
+ and aMHC-GFP
2 single cell suspensions from 14 day hEBs
demonstrated upregulation of the cardiac-specific genes myosin
light chain-2 ventricular (MLC2v), cardiac troponin I (cTnI),
myocyte-specific/MADS box transcription enhancer factor 2C
(Mef2c), GATA4, cyclin-dependent kinase inhibitor p21
Cip1, and
stem cell factor/c-kit ligand (SCF), and downregulation of the
pluripotency factor, Nanog, as well as ectoderm-specific bIII-
tubulin (bIII-tub) and the primitive endoderm marker, a-
fetoprotein (AFP) in aMHC-GFP
+ compared to aMHC-GFP
2
cells. Data shown represent mean6s.e.m. (N=5).
(TIF)
Figure S2 miR-125b expression is similar between
differentiating H7 and H9 hESCs. Relative expression of
endogenous miR-125b in undifferentiated, wild type H7 and H9
hESCs (Undiff) and wild type H7 and H9 hESCs grown in
differentiation medium for 2, 3, 4, 8, and 14 days was assessed by
qPCR. Similar expression patterns were seen over the course of
differentiation for both lines (top). Nanog expression was analyzed
in parallel as an inverse measure of hESC differentiation (bottom).
Although miR-125b expression appears to be downregulated with
differentiation of unselected hESC populations as shown here, it is
specifically upregulated in differentiating CMs as shown in
Figure 2A, where 8 and 14 day samples contain selected
aMHC-GFP
+ myocardial cells. This supports a mesoderm- and
CM-specific role for miR-125b. Data shown are mean6s.e.m.
(N=4).
(TIF)
Table S1 Conserved human miR-125b targets with
aggregate probability of conserved targeting (PCT)
.0.95.
(DOCX)
Table S2 Conserved human miR-125b targets with total
context score #20.45.
(DOCX)
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